No plans to reintroduce Zinetac in India: GSK

British drugmaker GSK said it has no plans to reintroduce its once top-selling heartburn medication Zinetac (ranitidine) brand in India, despite the US court last week ruling that there is no sound scientific evidence to back the claims that the drug increases the risk of cancer.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news